3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Metastatic Solid Tumors
2
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
1
Recurrence
1
Prostate Cancer Patients Undergoing Radical Prostatectomy
1
Neoadjuvant Treatment for Locally Advanced Cervical Cancer
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Azacitidine
25
venetoclax
19
Cyclophosphamide
17
fludarabine phosphate
14
Whole-Body Irradiation
13
Biopsy
13
fludarabine
12
Specimen Handling
12
Tacrolimus
11
Mycophenolic Acid
11
Decitabine
10
Stem Cell Transplantation
9
Peripheral Blood Stem Cell Transplantation
9
Injections
8
Cytarabine
8
Busulfan
8
decitabine and cedazuridine drug combination
7
Melphalan
7
X-Rays
5
Hematopoietic Stem Cell Transplantation
5
Cyclosporine
5
Sirolimus
4
ruxolitinib
3
olutasidenib
3
enasidenib
3
cedazuridine
3
Magnetic Resonance Spectroscopy
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelomonocytic, Chronic
×
Infusions, Intravenous
×
1 year
×
Clear all
NCT03850574
2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2
Recruiting
240 enrolled